30 / 63
ELIGIBILITY CRITERIA
•
Patients aged ≥ 18 years
•
Histologically or cytologically confirmed (N2) Stage IIIA NSCLC (7
th
edition)
•
Resectable tumor
•
ECOG Performance Status 0-1
•
Forced expiratory volume (FEV1) ≥ 1.2 liters
•
Adequate hepatic, hematological and renal functions
•
EGFR and ALK mutated patients are ineligible
STUDY OBJECTIVES
•
Progression-free survival (PFS) at 24 months
(primary)
•
Down-staging rate, complete resection rate and response rate (RR)
•
Toxicity profile
•
Time to progression and 3-year overall survival
•
Surgical outcome and operative and post-operative complications
•
To explore the expression of other biomarkers
•
To determine whether PD-L1 expression is a predictive biomarker for ORR
•
To determine PFS in PD-L1+ (≥ 1%) population